| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/500-1/1000 | Human,Mouse,Rat |
| Aliases | C20orf31; C20orf49; bA4204.1 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human EDEM2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于EDEM2抗体的3篇参考文献示例(注：文献信息为模拟概括，仅供参考)：
1. **文献名称**：*EDEM2 accelerates ER-associated degradation of misfolded glycoproteins through direct recognition of terminal mannose*
**作者**：Ninagawa, S. et al.
**摘要**：本研究揭示了EDEM2通过识别错误折叠糖蛋白末端的甘露糖结构，直接参与内质网相关降解(ERAD)的分子机制。作者利用特异性EDEM2抗体进行免疫共沉淀和免疫荧光实验，证实EDEM2与ERAD关键组分(如OS-9)的相互作用及其在内质网中的定位。
2. **文献名称**：*The ER-resident protein EDEM2 regulates the turnover of ERAD substrates via its mannosidase-like domain*
**作者**：Hosokawa, N. et al.
**摘要**：通过Western blot和免疫组化技术(使用EDEM2特异性抗体)，研究者证明EDEM2的类甘露糖苷酶结构域对错误折叠蛋白的识别至关重要。实验表明EDEM2缺失会延缓ERAD底物的降解，并激活未折叠蛋白反应(UPR)。
3. **文献名称**：*EDEM2-dependent trimming of oligomannose glycans directs glycoprotein quality control in the ER*
**作者**：Mast, S.W. et al.
**摘要**：该研究通过EDEM2抗体介导的蛋白质组学分析，发现EDEM2通过剪切高甘露糖型聚糖标记异常糖蛋白，促进其靶向蛋白酶体降解。实验数据支持EDEM2在维持内质网稳态中的关键作用。
**提示**：实际文献需通过PubMed/Google Scholar检索确认。建议使用关键词“EDEM2 antibody”或“EDEM2 ERAD”筛选近年研究，重点关注方法学中明确使用抗体的论文。
The EDEM2 (ER degradation-enhancing α-mannosidase-like protein 2) antibody is a tool used to study the ER-associated degradation (ERAD) pathway, a critical quality control system in the endoplasmic reticulum (ER). EDEM2. a member of the EDEM family (EDEM1-3), facilitates the recognition and targeting of misfolded glycoproteins for proteasomal degradation. Unlike EDEM1 and EDEM3. EDEM2 lacks enzymatic mannosidase activity but acts as a lectin-like chaperone, binding to high-mannose oligosaccharides (e.g., Man8GlcNAc2) on unfolded glycoproteins to accelerate their ERAD. It collaborates with ER-resident chaperones like BiP/GRP78 and interacts with ERAD machinery components such as SEL1L-HRD1.
EDEM2 antibodies are widely employed in research to investigate protein quality control mechanisms, ER stress responses, and diseases linked to ERAD dysfunction, including neurodegenerative disorders (e.g., Alzheimer’s, Parkinson’s), metabolic syndromes, and cancer. These antibodies enable detection and localization of EDEM2 via techniques like Western blotting, immunofluorescence, and immunoprecipitation. Studies using EDEM2 antibodies have revealed its role in regulating the stability of specific substrates, such as α1-antitrypsin variants, and its involvement in adaptive ER stress pathways like the unfolded protein response (UPR). Recent research also explores its potential as a therapeutic target for conditions associated with protein misfolding. Antibodies are typically raised in rabbits or mice, with validation in knockout models ensuring specificity.
×
